Oruka Therapeutics (NASDAQ:ORKA) Shares Gap Up – Still a Buy?

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $72.34, but opened at $81.00. Oruka Therapeutics shares last traded at $82.4510, with a volume of 400,989 shares traded.

Analysts Set New Price Targets

ORKA has been the topic of several research reports. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Monday, April 27th. Stifel Nicolaus lifted their price target on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. UBS Group upped their price objective on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Finally, Barclays increased their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $131.30.

Oruka Therapeutics Trading Up 18.1%

The firm’s 50 day simple moving average is $64.73 and its 200-day simple moving average is $45.48. The stock has a market capitalization of $5.15 billion, a price-to-earnings ratio of -43.98 and a beta of -0.25.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. As a group, equities research analysts predict that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total value of $120,494.01. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $64,503,670.20. This trade represents a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Carl Dambkowski sold 12,583 shares of the business’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $70.11, for a total transaction of $882,194.13. Following the transaction, the director owned 38,743 shares in the company, valued at approximately $2,716,271.73. The trade was a 24.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 183,820 shares of company stock worth $11,507,840. 23.49% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Legal & General Group Plc bought a new stake in Oruka Therapeutics in the second quarter valued at approximately $28,000. BNP Paribas Financial Markets lifted its stake in shares of Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after buying an additional 2,306 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after buying an additional 365 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the 4th quarter worth about $37,000. Finally, PNC Financial Services Group Inc. acquired a new position in Oruka Therapeutics in the 3rd quarter valued at about $39,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.